Literature DB >> 26499949

Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.

Bing Ma1, Meng Li2, Lei Zhang3, Ming Huang1, Jun-Bin Lei1, Gui-Hong Fu4, Chun-Xin Liu5, Qi-Wen Lai6, Qing-Quan Chen7, Yi-Lian Wang8.   

Abstract

The pathogenesis of osteosarcoma involves complex genetic and epigenetic factors. This study was to explore the impact and clinical relevance of long non-coding RNA (lncRNA), Taurine up-regulated gene 1 (TUG1) on patients with osteosarcoma. Seventy-six osteosarcoma tissues and matched adjacent normal tissues were included for analysis. The plasma samples were obtained from 29 patients with osteosarcoma at pre-operation and post-operation, 42 at newly diagnosed, 18 who experienced disease progression or relapse, 45 post-treatment, 36 patients with benign bone tumor, and 20 healthy donors. Quantitative real-time reverse transcript polymerase chain reactions were used to assess the correlation of the expression levels of TUG1 with clinical parameters of osteosarcoma patients. TUG1 was significantly overexpressed in the osteosarcoma tissues compared with matched adjacent normal tissues (P < 0.01) and was closely correlated with tumor size, post-operative chemotherapy, and Enneking surgical stage. Upregulation of TUG1 strongly correlated with poor prognosis and was an independent prognostic indicator for overall survival (HR = 2.78, 95% CI = 1.29-6.00, P = 0.009) and progression-free survival (HR = 1.81, 95% CI = 1.01-3.54, P = 0.037). Our constructed nomogram containing TUG1 had more predictive accuracy than that without TUG1 (c-index 0.807 versus 0.776, respectively). In addition, for plasma samples, TUG1 expression levels were obviously decreased in post-operative patients (mean ΔCT -4.98 ± 0.22) compared with pre-operation patients (mean ΔCT -6.09 ± 0.74), and the changes of TUG1 expression levels were significantly associated with disease status. Receiver operating characteristic (ROC) curve analysis demonstrated that TUG1 could distinguish patients with osteosarcoma from healthy individuals compared with alkaline phosphatase (ALP) (the area under curve 0.849 versus 0.544). TUG1 was overexpressed in patients with osteosarcoma and strongly correlated with disease status. In addition, TUG1 may serve as a molecular indicator in maintaining surveillance and forecasting prognosis.

Entities:  

Keywords:  Osteosarcoma; Prognosis; TUG1; lncRNA

Mesh:

Substances:

Year:  2015        PMID: 26499949     DOI: 10.1007/s13277-015-4301-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

Review 1.  Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  S Bielack; D Carrle; P G Casali
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

Review 2.  Long noncoding RNAs: functional surprises from the RNA world.

Authors:  Jeremy E Wilusz; Hongjae Sunwoo; David L Spector
Journal:  Genes Dev       Date:  2009-07-01       Impact factor: 11.361

3.  Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses.

Authors:  Moran N Cabili; Cole Trapnell; Loyal Goff; Magdalena Koziol; Barbara Tazon-Vega; Aviv Regev; John L Rinn
Journal:  Genes Dev       Date:  2011-09-02       Impact factor: 11.361

4.  Investigation of circulating lncRNAs in B-cell neoplasms.

Authors:  Mustafa Isin; Emre Ozgur; Guven Cetin; Nilgun Erten; Melih Aktan; Ugur Gezer; Nejat Dalay
Journal:  Clin Chim Acta       Date:  2014-02-26       Impact factor: 3.786

5.  Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

Authors:  Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

6.  MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.

Authors:  Yongqiang Dong; Guojun Liang; Bo Yuan; Chaoqun Yang; Rui Gao; Xuhui Zhou
Journal:  Tumour Biol       Date:  2014-11-28

7.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Hagop Kantarjian; Michael Keating
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

8.  Circulating long non-coding RNAs in plasma of patients with gastric cancer.

Authors:  Tomohiro Arita; Daisuke Ichikawa; Hirotaka Konishi; Shuhei Komatsu; Atsushi Shiozaki; Katsutoshi Shoda; Tsutomu Kawaguchi; Shoji Hirajima; Hiroaki Nagata; Takeshi Kubota; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Anticancer Res       Date:  2013-08       Impact factor: 2.480

9.  Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report.

Authors:  Timothy A Damron; William G Ward; Andrew Stewart
Journal:  Clin Orthop Relat Res       Date:  2007-06       Impact factor: 4.176

10.  A novel long non-coding RNA, hypoxia-inducible factor-2α promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro.

Authors:  Yongcheng Wang; Jie Yao; Haoye Meng; Zhiguo Yu; Zhigang Wang; Xueling Yuan; Hong Chen; Aiyuan Wang
Journal:  Mol Med Rep       Date:  2014-12-01       Impact factor: 2.952

View more
  53 in total

Review 1.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

Review 2.  Long non-coding RNAs: emerging players in osteosarcoma.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-12-30

Review 3.  Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Authors:  Zhimin Yang; Tang Liu; Xiaolei Ren; Mei Yang; Chao Tu; Zhihong Li
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

4.  Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression.

Authors:  Chu-Hai Xie; Yan-Ming Cao; Yan Huang; Qun-Wei Shi; Jian-Hong Guo; Zi-Wen Fan; Ju-Gen Li; Bin-Wei Chen; Bo-Yi Wu
Journal:  Tumour Biol       Date:  2016-09-22

5.  Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p.

Authors:  Lei Zhao; Weiguo Li; Hao Zhao
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

Review 6.  TUG1: a pivotal oncogenic long non-coding RNA of human cancers.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-06-23       Impact factor: 6.831

Review 7.  Emerging roles for long noncoding RNAs in skeletal biology and disease.

Authors:  Nguyen P T Huynh; Britta A Anderson; Farshid Guilak; Audrey McAlinden
Journal:  Connect Tissue Res       Date:  2016-06-02       Impact factor: 3.417

8.  Long noncoding RNA expression in the cervix mid-pregnancy is associated with the length of gestation at delivery.

Authors:  Heather H Burris; Allan C Just; Miriam J Haviland; Dayna T Neo; Andrea A Baccarelli; Alexandra E Dereix; Kasey J Brennan; Rodosthenis S Rodosthenous; Steven J Ralston; Jonathan L Hecht; Michele R Hacker
Journal:  Epigenetics       Date:  2018-08-10       Impact factor: 4.528

9.  Clinical significance of long noncoding RNA SPRY4-IT1 in melanoma patients.

Authors:  Teng Liu; Song-Ke Shen; Jian-Gui Xiong; Yuan Xu; Han-Qi Zhang; Hai-Jun Liu; Zheng-Gen Lu
Journal:  FEBS Open Bio       Date:  2016-02-03       Impact factor: 2.693

10.  Long noncoding RNA taurine-up regulated gene 1 for the prognosis of osteosarcoma: A protocol for meta-analysis and bioinformatics analysis.

Authors:  Zheng Ren; Chenyang Li; Yuling Gan; Xiuxin Liu; Fudong Liang
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.